02376nas a2200289 4500008004100000245011800041210006900159260001800228300001000246490000600256520148400262653002101746653001801767653002401785653001601809653001301825100002001838700002101858700001801879700002501897700001701922700001801939700001801957700002201975700002501997856006402022 2013 eng d00aAnti-atherogenic and Anti-ischemic Potentials of Croton Membranaceus Observed During Sub-chronic Toxicity Studies0 aAntiatherogenic and Antiischemic Potentials of Croton Membranace cJanuary 2013 a10-160 v53 a

Background : Croton membranaceus (CM) is used for benign prostate hyperplasia treatment. Objective : Sub-chronic toxicity studies are non-existent and provided the basis for this study. Materials and Methods : 90 days oral administration of a low dose (LD) (30 mg/kg b. wt.), medium dose (MD) (150 mg/kg b. wt.), and high dose (HD) (300 mg/kg b. wt.) CM aqueous root extract to 3 groups (n=6 each) of male Sprague-Dawley rats, alongside a control group, was undertaken. Urinalysis, hepato-renal function tests, lipid profile, cardiac enzymes, and routine hematology tests were performed. Results : Triglyceride levels (C=1.05±0.19, LD=0.64±0.08, MD=0.55±0.04, HD=0.50±0.02 mmol/L) were significantly reduced (P<0.05). Very low density lipoprotein (C=0.48±0.09, LD=0.29±0.04, MD=0.25±0.02, HD=0.23±0.01 mmol/L) decreased significantly (P<0.05). Cardiac enzymes-creatinine kinase (C=568±172, LD=315±79, MD=441±209, HD=286±81 IU/L) decreased markedly (P<0.05) alongside lactate dehydrogenase (C=2675±875, LD=1667±1229, MD=1186±442, HD=855±239 IU/L) (P<0.05). Conclusion : C. membranaceus aqueous root extract is non-toxic but demonstrates anti-atherogenic and anti-ischemic potentials.

10aAnti-atherogenic10aAnti-ischemic10aCroton Membranaceus10aSub-chronic10aToxicity1 aAfriyie, Dan, K1 aAsare, George, A1 aBugyei, Kwasi1 aAsiedu-Gyekye, Isaac1 aGyan, Ben, A1 aAdjei, Samuel1 aAddo, Phyllis1 aSittie, Archibald1 aNyarko, Alexander, K uhttps://phcogres.com/article/2013/5/1/1041030974-8490105640